Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination regimen of three antibiotics—cefuroxime, flucloxacillin, and metronidazole—used together for broad-spectrum antibacterial coverage. - **Cefuroxime** is a second-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis, effective against many Gram-positive and some Gram-negative bacteria[8]. - **Flucloxacillin** is a narrow-spectrum beta-lactam antibiotic (penicillin class) that targets mainly Gram-positive organisms, especially Staphylococcus aureus (including penicillinase-producing strains), by inhibiting cell wall synthesis. - **Metronidazole** is an antimicrobial agent particularly active against anaerobic bacteria and certain protozoa; it disrupts DNA synthesis in susceptible organisms[7]. The combination provides comprehensive coverage for mixed infections involving aerobic Gram-positive cocci (notably staphylococci), some Gram-negative bacilli, and anaerobes. It may be used as empirical therapy in surgical prophylaxis or treatment of polymicrobial infections such as intra-abdominal sepsis or complicated skin/soft tissue infections where both aerobic and anaerobic pathogens are likely to be present[4][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefuroxime + flucloxacillin + metronidazole.